Abstract
The aim of this study was to verify the tolerability and efficacy of therapeutic chemotherapy protocols, employing different combinations of cis-platin, carbo-platin, etoposide and carmustine in primary glioblastoma patients. The purpose was focused on 2 end points: the response index to treatment, the TTP (tumor progression) and the ST (survival time). Eighty-four out of a group of 99 consecutive glioblastoma patients, entered this study. Patients were divided into 4 disparate treatment groups: (A) BCNU alone; (B) CDDP+VP-16; (C) CBDCA+BCNU; (D) CBDCA+BCNU+VP-16. The effectiveness and the TTP of the protocols differed, but differences were not statistically significant. Data concerning platinum treatment compare favorably with the best literature results. At 18 months more than half the carboplatin-treated patients are alive. Moreover these patients had a significantly longer ST than those treated with BCNU. We conclude that platinum-based chemotherapy has a beneficial effect on glial tumors.
Sommario
Scopo di questo studio è stato quello di verificare la tollerabilità ed efficacia di alcuni differenti protocolli chemioterapici. Ai fini dello studio sono stati trattati 84 Pazienti affetti da glioblastoma e valutati il Time to tumor progression e Survival Time. I Pazienti sono stati divisi in quattro differenti gruppi terapeutici: a) BCNU b) CDDP+VP-16 c) CBDCA+BCNU e) CBDCA+VP-16+BCNU. A 18 mesi oltre la metà dei pazienti trattati con schemi contenenti platino derivati sono sopravvissuti, con un Survival time significativamente più lungo rispetto a quello dei pazienti trattati con solo BCNU. Le differenze tra i vari gruppi del Time to tumor progression non sono risultate invece statisticamente significative.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bertolone,S.J., Baum E.S., Krivit W., Hammound G.D.:A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Children's Cancer Study Group. J. Neuro-Oncol. 7:5–11, 1989.
Boiardi A., Silvani A., Milanesi I. et al.:Primary glial tumor patients treated by combining cisplatin and etoposide. J. Neuro-oncology 11:165–170, 1991.
De Gregorio M., Wilbur B., King O. et al.:Peak cerebrospinal fluid platinum levels in a patients with ependymona: evaluation of two different methods of cisplatin administration. Cancer Treat. Rep. 70:1437–1438, 1986.
Doz F., Berens M.E., Goughtery D.V., Rosenblum M.:Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J. Neuro-Oncol. 11:27–35, 1991.
Edwards M.S., Levin V.A., Wilson C.B.:Brain tumor chemotherapy: an evaluation of agent use for phase II and III trials. Cancer Treat. Rep. 64:1179–1205, 1980.
Khan A.B., D'Souza B.J., Wharam M. et al.:Cisplatin in therapy in recurrent childhood brain tumors. Cancer Treat. Rep. 66:2013, 1982.
Kornblith P., Walker M.:Chemotherapy for malignant gliomas. J. Neurosurg 68:1–17, 1988.
Krauseneck P., Mertens H.G.:Results of chemotherapy of malignant brain tumors in adults. In therapy of malignant brain tumors. Ed by Kurt Jellinger, Springer-Verlag, Vienna & New York 1987.
Levin V.A., Sheline G.E., Gutin P.H. in: De Vita V.T. Jr, Hellman S., Rosenberg S.A., eds:Neoplasms of the Central Nervous System: Cancer principles and practice in oncology. Philadelphia, J.B. Lippincott Co, 1557–1611, 1989.
Siddik Z.H., Jones M., Boxall F.E., Harrap K.R.:Comparative distribution of carboplatin and cisplatin in mice. Cancer chemother & Pharmacol 21:12–24, 1988.
Soranzo C., Pratesi G., Zunino F.:Different interaction of cisplatin and etoposide on in vivo and in vitro tumor system. Anti-cancer Drugs 1:23–27, 1990.
Steward D.J., O'Bryan R.M., Al-Sarraf M.:Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J. Neuro-Oncol. 1:145–147, 1983.
Stewart D.J., Benjamin R.S., Luna M. et al.:Human tissue distribution of platinum after cisdiamminedichloroplatinum. Cancer Chemother & Pharmacol. 10:51–54, 1982.
Stewart D.J., Richard M.T., Hugenholtz H. et al.:Penetration of VP-16 into human intracerebral and extracerebral tumors. J. Neuro-Oncol. 2:133–139, 1984.
Trump D.L., Grem J.L., Tutsch K.D.:Platinum analogue combination chemotherapy; cisplatin and carboplatin. A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J. Clin. Oncol. 5:1281–1289, 1987.
Walker R.W., Allen J.C.:Cisplantin in the treatment in recurrent childhood primary brain tumors. J. Clin. Oncol. 6:62–66, 1988.
Zucchetti M., Rossi C., Knerich R. et al.:Concentration of VP-16 and VM-26 in human brain tumors. Annals of Oncology 2:63–66, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boiardi, A., Silvani, A., Milanesi, I. et al. Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma. Ital J Neuro Sci 13, 717–722 (1992). https://doi.org/10.1007/BF02229155
Issue Date:
DOI: https://doi.org/10.1007/BF02229155